Literature DB >> 8749644

Prognostic significance of quantitative bacteremia in septicemic melioidosis.

A L Walsh1, M D Smith, V Wuthiekanun, Y Suputtamongkol, W Chaowagul, D A Dance, B Angus, N J White.   

Abstract

Pour-plate blood cultures were performed for 418 adult patients with suspected septicemic melioidosis in order to determine the relationship between quantitative bacterial counts in blood and mortality. Of 108 patients whose hemocultures yielded Burkholderia pseudomallei, 53% had < 10 cfu/mL and 24% had > 100 cfu/mL. High blood bacterial counts were more common than reported previously with regard to other gram-negative septicemias and were significantly associated with the development of hypotension (P = .008) and a fatal outcome (P = .0001). The overall mortality was 63% (95% CI, 53%-72%); however, counts of < or = 1 cfu/mL were associated with a mortality of 42% (95% CI, 28%-58%), compared with 96% (95% CI, 80%-100%) with counts of > 100 cfu/mL. Heavy bacteremia (> 50 cfu/mL) is common in septicemic melioidosis and is usually fatal.

Entities:  

Mesh:

Year:  1995        PMID: 8749644     DOI: 10.1093/clinids/21.6.1498

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  27 in total

1.  Rapid identification of Burkholderia pseudomallei in blood cultures by a monoclonal antibody assay.

Authors:  S Pongsunk; N Thirawattanasuk; N Piyasangthong; P Ekpo
Journal:  J Clin Microbiol       Date:  1999-11       Impact factor: 5.948

2.  Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis.

Authors:  B J Angus; M D Smith; Y Suputtamongkol; H Mattie; A L Walsh; V Wuthiekanun; W Chaowagul; N J White
Journal:  Br J Clin Pharmacol       Date:  2000-08       Impact factor: 4.335

3.  Development and evaluation of a real-time PCR assay targeting the type III secretion system of Burkholderia pseudomallei.

Authors:  Ryan T Novak; Mindy B Glass; Jay E Gee; Daniel Gal; Mark J Mayo; Bart J Currie; Patricia P Wilkins
Journal:  J Clin Microbiol       Date:  2006-01       Impact factor: 5.948

Review 4.  Sensing gram-negative bacterial lipopolysaccharides: a human disease determinant?

Authors:  Robert S Munford
Journal:  Infect Immun       Date:  2007-12-17       Impact factor: 3.441

Review 5.  Human Melioidosis.

Authors:  I Gassiep; M Armstrong; R Norton
Journal:  Clin Microbiol Rev       Date:  2020-03-11       Impact factor: 26.132

6.  Clinical evaluation of a type III secretion system real-time PCR assay for diagnosing melioidosis.

Authors:  Ella M Meumann; Ryan T Novak; Daniel Gal; Mirjam E Kaestli; Mark Mayo; Joshua P Hanson; Emma Spencer; Mindy B Glass; Jay E Gee; Patricia P Wilkins; Bart J Currie
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

7.  Changing trends in etiology of bacteremia in patients with cancer.

Authors:  A Safdar; G H Rodriguez; M Balakrishnan; J J Tarrand; K V I Rolston
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-08       Impact factor: 3.267

8.  A comparison of lysis centrifugation, pour plate, and conventional blood culture methods in the diagnosis of septicaemic melioidosis.

Authors:  A J Simpson; P A Howe; V Wuthiekanun; N J White
Journal:  J Clin Pathol       Date:  1999-08       Impact factor: 3.411

9.  Towards a rapid molecular diagnostic for melioidosis: Comparison of DNA extraction methods from clinical specimens.

Authors:  Leisha J Richardson; Mirjam Kaestli; Mark Mayo; Jolene R Bowers; Apichai Tuanyok; Jim Schupp; David Engelthaler; David M Wagner; Paul S Keim; Bart J Currie
Journal:  J Microbiol Methods       Date:  2011-11-12       Impact factor: 2.363

10.  Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis.

Authors:  B J Angus; M D Smith; Y Suputtamongkol; H Mattie; A L Walsh; V Wuthiekanun; W Chaowagul; N J White
Journal:  Br J Clin Pharmacol       Date:  2000-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.